VR Logo

Vaccitech plc (VACC) download report


Healthcare | Biotechnology & Pharma Research

Vaccitech plc (VACC) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.

IPO Date: 30-Apr-2021

CEO & Director: Mr. William J. Enright MBA

Chief Financial Officer: Mr. Georgy Egorov

Listing: NASDAQ: VACC

Country: United Kingdom

Headquarters: Oxford,

Website: https://www.vaccitech.co.uk

Key Facts

Market cap: $219.30 Mln

Revenue (TTM): $15.07 Mln

Earnings (TTM): $-32.34 Mln

Cash: $200.60 Mln

Total Debt: $6.74 Mln

Insider's Holding: 27.55%

Liquidity: Low

52 Week range: $2.97 - 17.99

Shares outstanding: 37,200,300

Stock Performance

Time Period Vaccitech (VACC) S&P BSE Sensex* S&P Small-Cap 600*
YTD-47.52-8.71-17.14
1 month33.11-3.11-4.85
3 months29.27-7.30-12.74
1 Year-61.620.48-16.37
3 Years--10.347.97
5 Years--11.436.33
10 Years--12.1010.54
As on 27-Jun-2022 *As on 28-Jun-2022